Why PuraPly® Antimicrobial?

It is estimated that biofilm, the polymeric film that makes it difficult to eliminate pathogens,1 is present in 60% of chronic wounds.2 Topical antimicrobials, such as some silver preparations, have demonstrated cytotoxic effects associated with delayed healing,3,4 whereas PuraPly Antimicrobial utilizes PHMB,5 a noncytotoxic antimicrobial substance known to inhibit the formation of biofilm on the wound surface.6

Learn more about the benefits of collagen and PHMB here.

PuraPly Antimicrobial Demonstrated Substantial Reduction in Biofilm-Associated Bacteria in Preliminary Study7

PuraPly Antimicrobial substantially reduced MRSA as compared to PriMatrix® Ag and Endoform™—as early as 2 days after initial medical intervention.7 View the data from the preliminary study.

References: 1. Mulder GD, Cavorsi JP, Lee DK. Wounds. 2007;19(7):173-182. 2. Wolcott R, Cutting KF, Ruiz JC. Association for the Advancement of Wound Care. Publication No. UKCT-A0021. 2008:12-17. 3. Zou SB, Yoon WY, Han SK, Jeong SH, Cui ZJ, Kim WK. Int Wound J. 2013;10(3):306-312. 4. Storm-Versloot MN, Vos CG, Ubbink DT, Vermeulen H. Cochrane Database Syst Rev. 2010;(3):CD006478. 5. PuraPly Antimicrobial [package insert]. Canton, MA: Organogenesis, Inc; 2015. 6. Hübner NO, Kramer A. Skin Pharmacol Physiol. 2010;23(suppl):17-27. 7. Davis SC, Gil J, Valdes J, et al. Preliminary evaluation of a purified collagen matrix with polyhexamethylene biguanide (PHMB) antimicrobial reducing methicillin resistant Staphylococcus aureus infections using a porcine deep dermal wound model. Poster presented at: 9th Annual Symposium for Advanced Wound Care; October 20-22, 2017; Las Vegas, NV.